Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

NCT04524884 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04524884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2020
Completion date
September 30, 2022
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer